The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Prognostic and predictive role of ctDNA in stage III colon cancer treated with celecoxib
Jonathan Nowak, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib enrolled in the CALGB SWOG 80702 study, a Phase III trial investigating the efficacy of adjuvant FOLFOX therapy and celecoxib in stage three colon cancer patients. Dr Nowak highlights that baseline ctDNA positivity after surgery was strongly predictive of shorter disease-free survival (DFS) and overall survival (OS). This analysis suggests that ctDNA positivity can be used as a biomarker to predict patients’ response to celecoxib, with a significant benefit observed in ctDNA-positive patients, where celecoxib improved DFS and OS by about 44% compared to 22-23% in ctDNA-negative patients. This result has implications for personalized adjuvant therapy selection in colorectal cancer. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
